Background Stroke thrombolysis with alteplase is currently recommended 0–4·5 h after
stroke onset. We aimed to determine whether perfusion imaging can identify patients with …

Background Trials of endovascular therapy for ischemic stroke have produced variable
results. We conducted this study to test whether more advanced imaging selection, recently …

Background The time to initiate intravenous thrombolysis for acute ischemic stroke is generally
limited to within 4.5 hours after the onset of symptoms. Some trials have suggested that …

Background Intravenous infusion of alteplase is used for thrombolysis before endovascular
thrombectomy for ischemic stroke. Tenecteplase, which is more fibrin-specific and has longer …

Background Intravenous alteplase is the only approved treatment for acute ischemic stroke.
Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an …

It is unknown whether collateral vessel status, as seen on computed tomography angiography,
can predict the fate of penumbral tissue identified on perfusion computed tomography …

Background The benefit of combined treatment with intravenous thrombolysis before
endovascular thrombectomy in patients with acute ischaemic stroke caused by large vessel …

Importance Intravenous thrombolysis with tenecteplase improves reperfusion prior to
endovascular thrombectomy for ischemic stroke compared with alteplase. Objective To determine …

Background and Hypothesis Thrombolysis with tissue plasminogen activator is proven to
reduce disability when given within 4.5 h of ischemic stroke onset. However, tissue …

Background: Tenecteplase is a modified tissue plasminogen activator with a longer half-life
and higher fibrin specificity than alteplase. Methods: We conducted a prospective, …